Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov;29(11):e13530.
doi: 10.1111/srt.13530.

The CDX2 G allele and the FoKI F allele of the VDR gene are more prevalent and related to changes in vitamin D levels in patients with psoriasis vulgaris: A pilot study

Ahmed Ibrahim AbdElneam  1   2 , Mohammed Saleh Al-Dhubaibi  3 , Saleh Salem Bahaj  4 , Mohammad Arshad  1 , Ghada Farouk Mohammed  5 , Lina Mohamed Atef  5
Affiliations

The CDX2 G allele and the FoKI F allele of the VDR gene are more prevalent and related to changes in vitamin D levels in patients with psoriasis vulgaris: A pilot study

Ahmed Ibrahim AbdElneam et al. Skin Res Technol. 2023 Nov.

Abstract

Background and aims: Psoriasis is a chronic, non-contagious autoimmune condition marked by dry, itchy,erythematous and scaly plaques. From modest, localized plaques to total body coverage, the severity of psoriasis varies. Plaque, guttate, inverted, pustular, and erythrodermic psoriasis are the five primary kinds. About 90% of cases are of plaque psoriasis, commonly known as psoriasis vulgaris. Study aims to determine the impact of an rs2228570 (FokI) variant and an rs11568820 (CDX2) variant on serum vitamin D levels (SVD) in patients with psoriasis, and the correlation between the two variants and disease severity.

Methods: A case-control study consisting of 95 psoriasis vulgaris patients and 84 healthy controls. The clinical investigation, molecular genetics analysis, and biochemical analysis were done for both groups.

Results: SVD levels were significantly decreased in psoriasis patients group. FokI genotypes analysis, we found no significant variance between groups. CDX2 G/G genotype is more prevalent in patients than controls. Moderate psoriasis vulgaris patients with CDX2 G/G genotypes have higher SVD levels than CDX2 G/A, and CDX2 A/A p = 0.003.

Conclusion: The study found a difference in vitamin D levels between patients and healthy subjects, as well as a difference in vitamin D levels with different FoKI and CDX2 genotypes.

Keywords: CDX2; FokI; psoriasis vulgaris; vitamin D.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(A) Lanes from 1 to 8 restriction enzyme analysis for rs2228570 the product appears at 267 bp and 204 for CT (F/f genotype). Lane M phi × 174 markers. (B) Partial sequence VDR gene PCR fragment rs 2228570 polymorphism 1. Showing only T peak indicating T/T (f/f genotypes) 2. Showing only C peak indicating C/C (F/F genotypes).
FIGURE 2
FIGURE 2
Lanes from 1 to 9 ARMS analysis for CDX2 variant the product appear at 110 bp G/G genotypes. Lane M (100 bp DNA Marker).
See this image and copyright information in PMC

References

    1. Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi:10.3390/ijms20061475 - DOI - PMC - PubMed
    1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983‐994. doi:10.1016/S0140-6736(14)61909-7 - DOI - PubMed
    1. Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM, Global Psoriasis Atlas . Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. Br J Dermatol. 2021;184(2):243‐258. doi:10.1111/bjd.19169 - DOI - PubMed
    1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301‐1315. doi:10.1016/S0140-6736(20)32549-6 - DOI - PubMed
    1. Yasmeen N, Sawyer LM, Malottki K, LÅ Levin, Didriksen Apol E, Jemec GB. Targeted therapies for patients with moderate‐to‐severe psoriasis: a systematic review and network meta‐analysis of PASI response at 1 year. J Dermatolog Treat. 2022;33(1):204‐218. doi:10.1080/09546634.2020.1743811 - DOI - PubMed